AudioCure Pharma Advances Trial Testing of AC102 for Sudden Hearing Loss Treatment
AudioCure Pharma has surpassed 50% patient enrollment in its Phase 2 trial testing AC102, a novel therapy to treat sudden hearing loss.
AudioCure Pharma has surpassed 50% patient enrollment in its Phase 2 trial testing AC102, a novel therapy to treat sudden hearing loss.
A team led by researchers at the University of Maryland School of Medicine (UMSOM) has published an online interactive atlas representing the changes in the levels of RNA made in the different cell types in ears of mice, after damage due to loud noise. These changes in RNA levels are known as changes in “gene expression.”
The Hearing Restoration Project (HRP) is an international consortium of researchers dedicated to finding cure(s) for hearing loss and tinnitus. HRP scientists work to understand how to regenerate dead or inactive inner ear hair cells in the mouse with the ultimate aim of replicating this process to restore hearing in humans.
By Erik Robinson, Senior Media Relations Specialist, OHSU New research reveals a key insight into...
Read MoreUsing zebrafish as a proxy, scientists have shed light on how changes to specific genes alter the coordinated direction that these cells are laid out.
Read MoreThis study suggests that not properly treating infections or other conditions that chronically affect the middle ear may lead to neural deficits and increased difficulties hearing in noisy environments.
Read MoreFurey was most recently Chief Operating Officer (COO) for Spark Therapeutics, a global gene therapy developer. This appointment will be effective at the next meeting of the board of directors of the company, in September 2019.
Read MoreThe clinicians will outline how they perform comprehensive balance evaluations and various methods of vestibular rehabilitation, including the use of virtual reality, in an audiology setting. They will also discuss outcome statistics following treatment and share case studies.
Read MoreUsher syndrome is an inherited disorder that reportedly accounts for almost half of all cases of deaf-blindness. There are three types of the disease that are differentiated based on the level of deafness (Type I – innate deafness; Type II – diminished hearing that does not worsen with time, and Type III -progressive decrease in hearing).
Read MoreA team led by Professor Karen B. Avraham, vice dean of the Sackler Faculty of Medicine at Tel Aviv University, has now created the first map of “methylation”–one of the body’s main epigenetic signals–that reflects the functioning of the inner ear in its entirety.
Read MoreComposing music when you have a severe hearing loss can be a real challenge. For example, one has to listen with high acuity to the musical tracks using headphones or in-ear monitors that, by nature, make hearing aid use very difficult or impossible. Here are some insights from an accomplished composer who has devised several solutions for the creation of great music.
Read MoreThe results of their research, reported August 22 in “Neuron,” reveal that TMC1, a protein discovered in 2002, forms a sound- and motion-activated pore that allows the conversion of sound and head movement into nerve signals that travel to the brain—a signaling cascade that enables hearing and balance.
Read MoreAkouos is developing targeted adeno-associated viral vector (AAV)-based gene therapies for sensorineural hearing loss, which results from dysfunction or damage to sensory cells and/or nerve fibers of the inner ear.
Read MoreBy comparing the effects of seliforant to meclizine, a drug with known anticholinergic side effects, and placebo, the SENS-111-202 study aims to confirm the absence of anticholinergic effects such as sedation and memory loss in patients receiving seliforant.
Read MoreIt has been estimated that 1 in 100 people around the world have a congenital inner ear condition known as semicircular canal dehiscence, a thinning of the bone enclosing the inner ear that can lead to vertigo in response to certain sounds, changes in atmospheric pressure, or coughing.
Read MoreData from the presented studies showed that SENS-401 protected inner ear function and enhanced sensory hair cell survival in preclinical models of acoustic trauma and, separately, cisplatin infusion.
Read MoreUsing a highly sensitive technique to measure and map cisplatin in mouse and human inner ear tissues, researchers found that forms of cisplatin build up in the inner ear.
Read MoreConducted by scientists at NIDCD—part of the National Institutes of Health (NIH)—the research offers new insight into how specialized sensory hair cells develop and function, providing opportunities for scientists to explore novel ways to treat hearing loss, balance disorders, and deafness.
Read More